Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-thioguanine + prednisone + vincristine + idarubicin + cytarabine + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Grupo Argentino de Tratamiento de la Leucemia Aguda
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intrathecal
01
Overview
This multi-agent chemotherapy regimen is a consolidation strategy used for pediatric patients with acute myeloid leukemia (AML). Developed and utilized by the Grupo Argentino de Tratamiento de la Leucemia Aguda (GATLA) in the GATLA 8-LMA-P'07 trial, the regimen consists of six drugs: 6-thioguanine (an antimetabolite), prednisone (a corticosteroid), vincristine (a vinca alkaloid), idarubicin (an anthracycline), cytarabine (an antimetabolite), and cyclophosphamide (an alkylating agent). The regimen aims to eliminate residual leukemic cells following induction therapy through multiple mechanisms, including DNA intercalation, inhibition of DNA synthesis, and induction of apoptosis. In the trial context, it served as the conventional consolidation comparator against a block therapy approach.
- Other names
- Conventional consolidation6-drug consolidationGATLA 8-LMA-P'07 Arm A
02
Targets
RNR (Ribonucleotide reductase)GR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)DNA polymerase familyDNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on 6-thioguanine + prednisone + vincristine + idarubicin + cytarabine + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 6-thioguanine + prednisone + vincristine + idarubicin + cytarabine + cyclophosphamide.